Navigation Links
NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002
Date:3/23/2011

KALAMAZOO, Mich., March 23, 2011 /PRNewswire/ -- NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis.  Previously, NephRx reported that NX002 had demonstrated significant efficacy when tested in well-validated animal models of oral mucositis.  Mucositis is a debilitating and often dose-limiting condition that affects more than 400,000 cancer patients who receive chemotherapy or radiation therapy in the U.S. each year.  Current treatment options are limited.

"Issuance of this most recent patent further confirms the promising utility of NX002 as a potential treatment for oral mucositis," said James Koziarz, President and CEO of NephRx.  "Mucositis is a painful and debilitating side effect of cancer therapy that can be dose-limiting, jeopardizing patients' chances for successful treatment.  We look forward to advancing the detailed NX002 toxicity studies needed to initiate the mucositis clinical program for NX002."

NX002 is a peptide derived from the naturally occurring growth factor AMP-18, which has been shown to stimulate the growth of epithelial cells and to promote mucosal wound healing after injury.  Its multiple biological properties include the ability to protect cells from injury, stimulate cell growth and migration, and increase the accumulation of proteins that bind cells together.  In a study in a well-validated mucositis model, animals treated with NX002 had reduced levels of oral ulceration and a more rapid recovery, with no evidence of toxicity.  NephRx has begun the preclinical toxicology studies of NX002 needed to initiate mucositis clinical trials targeted for late 2011 or early 2012.

The U.S. Patent and Trademark office issued Patent No. 7910543, "Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors."  Rights to this patent, which protects NX002 and related compounds, have been exclusively licensed to NephRx by the University of Chicago.

NX002 may also have applications in acute and chronic diseases of the gastrointestinal tract, such as Crohn's disease and ulcerative colitis.  It has been shown to stimulate the growth of epithelial cells and to promote mucosal wound healing after injury. 

About Oral MucositisMucositis is an inflammation and ulceration of the lining of the mouth, throat or gastrointestinal tract associated with cancer chemotherapy and radiation therapy.  The pain resulting from mucositis can be so severe that it is cited by patients as a major reason for discontinuing cancer treatment.  In severe cases, mucositis prevents eating and often results in hospitalization.  Mucositis afflicts approximately 15-40% of patients receiving standard-dose chemotherapy and 76-100% of patients receiving chemotherapy for bone marrow transplant.  It affects virtually all patients receiving radiation therapy for head and neck and gastrointestinal cancers.  In total, an estimated 400,000 patients are affected by mucositis each year in the U.S. alone, and the incidence is rising as use of radiation and chemotherapy increases. About NephRxNephRx Corporation is a clinical-stage biotechnology company dedicated to the discovery and development of therapeutic products for the treatment of acute kidney failure and other renal disorders, and diseases of the gastrointestinal tract, including mucositis, Crohn's disease and ulcerative colitis.  NX001 is currently in Phase I testing and will be developed initially for the treatment of delayed graft function in kidney transplant patients.  NX002 is in preclinical development as a treatment for oral mucositis, a common, painful and dose-limiting side effect of cancer chemotherapy and radiation therapy.  For more information, visit http://www.nephrx.com.Contacts:Corporate:Media:NephRx Corp.

GendeLLindheim BioCom PartnersPhilip A. Long

Barbara Lindheim(269) 838-4785

(212) 918-4650
'/>"/>

SOURCE NephRx Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
2. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
3. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
4. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
5. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
6. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
9. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
10. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
11. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 Many patients ... for their medication when a pharmacy just a few ... prescription.  To alleviate this problem Medicationdiscountcard.com has ... to see exactly how much their medication will cost ... Made Easy Medicationdiscountcard.com ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017  Abaxis, Inc. ... manufacturing point-of-care blood analysis instruments and consumables for the ... call to discuss its financial results for the third ... call will be at 4:15 p.m. ET on Thursday, ... for the third quarter fiscal year 2017 after the ...
(Date:1/19/2017)... ALTO, Calif. , Jan. 19, 2017   ... research, is excited to announce that the first ... Cancer Biology  (RP:CB) have been published in eLife ... this project represents the first practical evaluation of ... result in reproducible studies. Unlike other assessments of ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin ... pure essential oils, announced the company had a successful visit to the 2017 ECRM ... event gives companies that work in the nutritional, sports and health industries a chance ...
(Date:1/20/2017)... ... , ... Lice Troopers, the lice removal company based in South Florida, has ... holiday season. , “It happens every year around this time,” says owner, Arie ... which is the head-to-head gateway that lice need to spread.” , As children return ...
(Date:1/20/2017)... ... ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation in a ... has been life-saving as she has been on the trial for more than six ... ovarian cancer in 2009. She underwent standard chemotherapy but a year later went to ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is ... life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater ... spent her career as an educator interacting with countless women who had little knowledge ...
(Date:1/20/2017)... ... ... fine examination of how God handles sin, including how to let go of lingering guilt ... over ten long years has been waiting to release this powerful insight about forgiveness that ... serving the Lord for over twenty years, and he has been preaching and teaching the ...
Breaking Medicine News(10 mins):